| dc.contributor.author | Khozin, Sean | |
| dc.contributor.author | Dreyer, Nancy A. | |
| dc.contributor.author | Galante, Dominic | |
| dc.contributor.author | Liu, Raymond | |
| dc.contributor.author | Neumann, Peter | |
| dc.contributor.author | Nussbaum, Nathan | |
| dc.contributor.author | O’Shaughnessy, Joyce | |
| dc.contributor.author | Patt, Debra | |
| dc.contributor.author | Rimawi, Mothaffar | |
| dc.contributor.author | Rugo, Hope | |
| dc.contributor.author | Tolaney, Sara M. | |
| dc.contributor.author | Weiss, Marisa | |
| dc.contributor.author | Brufsky, Adam | |
| dc.date.accessioned | 2025-07-30T18:04:29Z | |
| dc.date.available | 2025-07-30T18:04:29Z | |
| dc.date.issued | 2025-05-12 | |
| dc.identifier.uri | https://hdl.handle.net/1721.1/162167 | |
| dc.description.abstract | Complementing randomized controlled trials, real-world evidence (RWE) from observational analyses can extend clinical insights in oncology. While healthcare stakeholders have published rigorous RWE frameworks and resources, a multidisciplinary think tank was established to further advance acceptance and use of RWE in treatment decision-making, with the focus on breast cancer (while recognizing relevance in oncology more broadly). Members discussed perceptions of RWE from a clinical perspective, across domains of data, methodology, and mindset, and “calls-to-action” for stakeholders. Agreement was reached on a primary “call-to-action,” to develop clinically-relevant, patient-informed, real-world endpoints, and secondary “calls-to-action”: establish a multidisciplinary consensus forum; publish examples of unique RWE value; build upon existing frameworks and resources; and tailor an approach for exhibiting utility to guideline bodies. | en_US |
| dc.publisher | Springer Healthcare | en_US |
| dc.relation.isversionof | https://doi.org/10.1007/s12325-025-03201-y | en_US |
| dc.rights | Creative Commons Attribution-Noncommercial | en_US |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | en_US |
| dc.source | Springer Healthcare | en_US |
| dc.title | Real-World Evidence Acceptability and Use in Breast Cancer Treatment Decision-Making in the United States: Call-to-Action from a Multidisciplinary Think Tank | en_US |
| dc.type | Article | en_US |
| dc.identifier.citation | Khozin, S., Dreyer, N.A., Galante, D. et al. Real-World Evidence Acceptability and Use in Breast Cancer Treatment Decision-Making in the United States: Call-to-Action from a Multidisciplinary Think Tank. Adv Ther 42, 2973–2987 (2025). | en_US |
| dc.contributor.department | Sloan School of Management | en_US |
| dc.relation.journal | Advances in Therapy | en_US |
| dc.identifier.mitlicense | PUBLISHER_CC | |
| dc.eprint.version | Final published version | en_US |
| dc.type.uri | http://purl.org/eprint/type/JournalArticle | en_US |
| eprint.status | http://purl.org/eprint/status/PeerReviewed | en_US |
| dc.date.updated | 2025-07-18T15:32:26Z | |
| dc.language.rfc3066 | en | |
| dc.rights.holder | The Author(s) | |
| dspace.embargo.terms | N | |
| dspace.date.submission | 2025-07-18T15:32:26Z | |
| mit.journal.volume | 42 | en_US |
| mit.license | PUBLISHER_CC | |
| mit.metadata.status | Authority Work and Publication Information Needed | en_US |